Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 34.0
(-2.3%)
SEK 34.0
(-2.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -129.49 Million SEK | -9.7% |
| 2022 | -118.04 Million SEK | 56.06% |
| 2021 | -268.64 Million SEK | 16.24% |
| 2020 | -320.74 Million SEK | -56.81% |
| 2019 | -204.54 Million SEK | 7.56% |
| 2018 | -221.26 Million SEK | -91.55% |
| 2017 | -115.51 Million SEK | -301.04% |
| 2016 | -28.8 Million SEK | -143.06% |
| 2015 | -11.85 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -68.75 Million SEK | 46.91% |
| 2024 Q2 | -91.73 Million SEK | -33.43% |
| 2023 Q2 | -30.59 Million SEK | 47.12% |
| 2023 Q1 | -57.85 Million SEK | 50.99% |
| 2023 Q4 | -129.49 Million SEK | 1.76% |
| 2023 Q3 | -131.81 Million SEK | -330.83% |
| 2023 FY | -129.49 Million SEK | -9.7% |
| 2022 Q2 | -140.1 Million SEK | 27.48% |
| 2022 Q3 | -87.62 Million SEK | 37.46% |
| 2022 Q1 | -193.21 Million SEK | 28.08% |
| 2022 FY | -118.04 Million SEK | 56.06% |
| 2022 Q4 | -118.04 Million SEK | -34.71% |
| 2021 FY | -268.64 Million SEK | 16.24% |
| 2021 Q2 | -249.52 Million SEK | 13.23% |
| 2021 Q3 | -212.81 Million SEK | 14.71% |
| 2021 Q4 | -268.64 Million SEK | -26.23% |
| 2021 Q1 | -287.57 Million SEK | 10.34% |
| 2020 Q4 | -320.74 Million SEK | -187.61% |
| 2020 FY | -320.74 Million SEK | -56.81% |
| 2020 Q3 | -111.52 Million SEK | 15.72% |
| 2020 Q2 | -132.32 Million SEK | 20.94% |
| 2020 Q1 | -167.38 Million SEK | 18.17% |
| 2019 Q3 | -125.35 Million SEK | 20.19% |
| 2019 FY | -204.54 Million SEK | 7.56% |
| 2019 Q1 | -184.57 Million SEK | 16.58% |
| 2019 Q2 | -157.06 Million SEK | 14.91% |
| 2019 Q4 | -204.54 Million SEK | -63.17% |
| 2018 Q4 | -221.26 Million SEK | -40.11% |
| 2018 FY | -221.26 Million SEK | -91.55% |
| 2018 Q1 | -188.88 Million SEK | -63.52% |
| 2018 Q2 | -171.81 Million SEK | 9.04% |
| 2018 Q3 | -157.92 Million SEK | 8.09% |
| 2017 Q2 | -12.02 Million SEK | -141.75% |
| 2017 Q3 | -137.67 Million SEK | -1045.03% |
| 2017 Q4 | -115.51 Million SEK | 16.1% |
| 2017 FY | -115.51 Million SEK | -301.04% |
| 2017 Q1 | 28.8 Million SEK | 200.0% |
| 2016 Q1 | 11.85 Million SEK | 0.0% |
| 2016 Q4 | -28.8 Million SEK | 0.0% |
| 2016 FY | -28.8 Million SEK | -143.06% |
| 2015 FY | -11.85 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Lipum AB (publ) | -8.46 Million SEK | -1429.77% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -158.881% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -579.407% |
| BioArctic AB (publ) | -606.58 Million SEK | 78.652% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -159.332% |
| Mendus AB (publ) | -96.29 Million SEK | -34.479% |
| Genovis AB (publ.) | -43.94 Million SEK | -194.702% |
| CombiGene AB (publ) | -101.44 Million SEK | -27.657% |
| Intervacc AB (publ) | -88.16 Million SEK | -46.886% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 731.375% |
| Active Biotech AB (publ) | -33.2 Million SEK | -290.045% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 343.306% |
| Ziccum AB (publ) | -2.13 Million SEK | -5959.663% |
| Camurus AB (publ) | -1.16 Billion SEK | 88.888% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -54.634% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -228.818% |
| Aptahem AB (publ) | 2.9 Million SEK | 4552.078% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 61.185% |
| Kancera AB (publ) | -45.69 Million SEK | -183.408% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 60.647% |
| Fluicell AB (publ) | -2.76 Million SEK | -4586.754% |
| Saniona AB (publ) | 40.44 Million SEK | 420.16% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -305.597% |
| Biovica International AB (publ) | -58.73 Million SEK | -120.466% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -186.386% |
| AcouSort AB (publ) | -23.98 Million SEK | -439.877% |
| Xintela AB (publ) | -7.8 Million SEK | -1558.279% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -340.715% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 177.973% |
| Abliva AB (publ) | -57.24 Million SEK | -126.232% |
| Corline Biomedical AB | -17.01 Million SEK | -661.198% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -57.533% |
| OncoZenge AB (publ) | -12.62 Million SEK | -925.541% |
| Amniotics AB (publ) | -5.63 Million SEK | -2199.272% |
| 2cureX AB (publ) | -13.4 Million SEK | -866.164% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 33.49% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -5892.365% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 2498.056% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 6.264% |
| I-Tech AB | -83.26 Million SEK | -55.527% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 196.13% |
| Cyxone AB (publ) | -16.67 Million SEK | -676.815% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -131.713% |
| Biosergen AB | -1.88 Million SEK | -6777.058% |
| Cantargia AB (publ) | -139.74 Million SEK | 7.336% |
| NextCell Pharma AB | -46.79 Million SEK | -176.754% |
| Nanologica AB (publ) | -9.38 Million SEK | -1279.367% |
| SynAct Pharma AB | -61.75 Million SEK | -109.681% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -504.693% |
| LIDDS AB (publ) | -13.51 Million SEK | -858.37% |
| BioInvent International AB (publ) | -236.3 Million SEK | 45.2% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -4257.167% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -878.859% |
| Alzinova AB (publ) | -21.22 Million SEK | -510.077% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -522.782% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -93.507% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -2399.46% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -54.638% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -13929.794% |
| Simris Alg AB (publ) | 85.07 Million SEK | 252.213% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -57.755% |